Skip to main content
Retour
EXEL logo

Exelixis, Inc.

Qualité des données : 100%
EXEL
NASDAQ Healthcare Biotechnology
41,57 €
▲ 0,16 € (0,39%)
Cap. Boursière : 11,15B
Fourchette du Jour
40,84 € 41,86 €
Fourchette 52 Semaines
32,38 € 49,62 €
Volume
2 365 781
Moyenne 50J / 200J
43,04 € / 41,57 €
Clôture Précédente
41,41 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 14,2 0,4
P/B 5,2 2,9
ROE % 35,5 3,9
Net Margin % 33,7 3,8
Rev Growth 5Y % 12,8 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
44,11 € +6.1%
Low: 30,00 € High: 54,00 €
P/E Prévisionnel
14,1
BPA Prévisionnel
2,95 €
Croissance BPA (est.)
+0,0%
CA Est.
2,3 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2031 5,48 €
4,92 € – 5,98 €
 3,2 B 6
FY2030 5,57 €
5,01 € – 6,09 €
 3,4 B 5
FY2029 4,77 €
2,26 € – 7,45 €
 3,3 B 12

Points Clés

Revenue grew 12,76% annually over 5 years — strong growth
Earnings grew 50,13% over the past year
ROE of 35,53% indicates high profitability
Net margin of 33,73% shows strong profitability
Debt/Equity of 0,08 — conservative balance sheet
Generating 844,34M in free cash flow

Croissance

Revenue Growth (5Y)
12,76%
Revenue (1Y)6,98%
Earnings (1Y)50,13%
FCF Growth (3Y)122,63%

Qualité

Return on Equity
35,53%
ROIC28,02%
Net Margin33,73%
Op. Margin37,59%

Sécurité

Debt / Equity
0,08
Current Ratio3,56
Interest Coverage0,00

Valorisation

P/E Ratio
14,24
P/B Ratio5,16
EV/EBITDA12,42
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6,98% Revenue Growth (3Y) 12,59%
Earnings Growth (1Y) 50,13% Earnings Growth (3Y) 94,08%
Revenue Growth (5Y) 12,76% Earnings Growth (5Y) 35,66%
Profitability
Revenue (TTM) 2,32B Net Income (TTM) 782,57M
ROE 35,53% ROA 27,51%
Gross Margin 96,39% Operating Margin 37,59%
Net Margin 33,73% Free Cash Flow (TTM) 844,34M
ROIC 28,02% FCF Growth (3Y) 122,63%
Safety
Debt / Equity 0,08 Current Ratio 3,56
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 14,24 P/B Ratio 5,16
P/S Ratio 4,80 PEG Ratio 0,25
EV/EBITDA 12,42 Dividend Yield 0,00%
Market Cap 11,15B Enterprise Value 10,84B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,32B 2,17B 1,83B 1,61B 1,43B
Net Income 782,57M 521,27M 207,77M 182,28M 231,06M
EPS (Diluted) 2,78 1,76 0,65 0,56 0,72
Gross Profit 2,24B 2,09B 1,76B 1,55B 1,38B
Operating Income 872,19M 604,62M 170,89M 201,48M 286,67M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,84B 2,95B 2,94B 3,07B 2,62B
Total Liabilities 683,10M 703,49M 678,45M 583,06M 405,62M
Shareholders' Equity 2,16B 2,24B 2,26B 2,49B 2,21B
Total Debt 173,04M 190,82M 189,94M 190,17M 51,27M
Cash & Equivalents 482,49M 217,37M 262,99M 501,20M 647,17M
Current Assets 1,44B 1,47B 1,32B 1,62B 1,83B
Current Liabilities 405,64M 403,77M 394,28M 324,36M 337,59M

Scores de Stratégies

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#964 of 1052
21
Custom Capital Light Compounder
#124 of 218
38
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#191 of 332
48
Custom Balanced Risk
#120 of 151
35
Custom Lower Risk
#113 of 140
35

Activité Récente

Entré Cash Flow Compounder
Mar 24, 2026
Entré Capital Light Compounder
Mar 24, 2026
Entré Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Entré Balanced Risk
Mar 24, 2026
Entré Lower Risk
Mar 24, 2026